A former Merck director's Pfizer-backed biotech will take on his old bosses in nascent LILRB field
Only a handful of biotechs are going after LILRBs, components of the innate immune system. But after an initial crop of data out of Merck in autumn 2020, more interest sprung up in the area, and a former Merck franchise director has secured investor backing to try to catch up to his former employer.
Zurich-area biotech ImmunOs Therapeutics reeled in a $74 million Series B to take that lead program into a Phase Ia study in Australia toward the end of this year, executives told Endpoints News. The drug, dubbed IOS-1002, is a multi-agent based on human leukocyte antigens (HLAs) that go after two versions of LILRB (1 and 2) and KIR3DL1.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
